BRIEF-Moody's Says $8.7 bln Acquisition Of Avexis Strengthens Novartis's Pipeline In Gene Therapy

* MOODY'S SAYS $8.7 BILLION ACQUISITION OF AVEXIS STRENGTHENS NOVARTIS'S PIPELINE IN GENE THERAPY, BUT REDUCES FINANCIAL FLEXIBILITY